
As evolving guidelines fold new regimens into category-one recommendations, keeping pace with which combinations qualify as frontline standard has become its own clinical and administrative challenge.

As evolving guidelines fold new regimens into category-one recommendations, keeping pace with which combinations qualify as frontline standard has become its own clinical and administrative challenge.

New data challenges a long-standing radiation practice: prophylactic cranial irradiation showed no survival benefit and worse cognitive outcomes, pushing the field toward closer monitoring instead of routine preventive treatment.

With comparable survival benefits and overlapping trial populations, choosing between two frontline immunotherapy regimens increasingly comes down to chemotherapy backbone flexibility and one drug's added indication across both disease stages.

Three-year survival data gives patients something rare in extensive-stage disease: a concrete number to hold onto. Nearly one in five patients alive at three years reframes what a durable tail of the curve can mean.

Two pivotal trials, built on different designs and chemotherapy backbones, delivered comparable, if modest, survival gains in extensive-stage disease, giving clinicians flexibility while leaving progression-free survival largely unmoved.

Extensive-stage small cell lung cancer resisted immunotherapy's promise longer than its non-small cell counterpart, but a small, durable subset of long-term survivors justified testing checkpoint inhibitors against a historically difficult tumor.

Seven oncology leaders at PCOC in Nashville share what patient-centered care means today and how they want it to change over the next 5 years.

Even with consolidation immunotherapy, most limited-stage patients still recur, a reminder that biomarker-driven approaches, earlier detection, and next-generation agents remain essential to moving survival further.

Logistics, not efficacy, often decide who completes limited-stage treatment. Distance from infusion centers, caregiver support, and clinic workflows can matter as much as the medicine itself in determining outcomes.

Tennessee Oncology's Wade Iams, MD, MSCI, discusses staffing and tocilizumab access as barriers to expanding BiTE therapy and the costs of cell therapy.

Despite a clear survival benefit, a meaningful share of eligible patients never receive consolidation immunotherapy after chemoradiation, exposing a gap between what trial data supports and what real-world practice actually delivers.

The ADRIATIC trial reshaped limited-stage treatment, extending median survival by nearly two years with consolidation immunotherapy, a shift so significant that adherence, not efficacy, is now the field's central clinical challenge.

Tennessee Oncology's Wade Iams, MD, MSCI, discusses insured patients' out-of-pocket costs, platinum shortages, and access to CAR T and BiTE therapies.

Concurrent chemoradiotherapy remains curative-intent therapy for limited-stage disease, yet cure rates without immunotherapy stall near thirty percent, a ceiling that scheduling choices and careful monitoring can only partly raise on their own.

Small cell lung cancer's stark divide between curable, localized disease and systemic, incurable disease shapes every treatment decision that follows, and screening gains are slowly shifting how many patients get caught early enough to benefit.

A medical expert discusses strategies that have successfully mitigated the economic impact of LEMS on patients and health care systems, and how a multidisciplinary approach can reduce the clinical and economic burden of LEMS on health care delivery.

A medical expert discusses how disparities in health care access affect the management and outcomes of Lambert-Eaton myasthenic syndrome (LEMS) in patients with small cell lung cancer, how health care providers can quantify the economic burden of LEMS on both patients and health care systems, the role of patient-reported outcomes in providing deeper insights into the clinical and economic burden of LEMS, and how health systems can utilize real-world data to better understand the indirect costs of LEMS.

A medical expert discusses how Lambert-Eaton myasthenic syndrome is closely linked to small cell lung cancer, the challenges in differentiating it from other neuromuscular disorders like myasthenia gravis, and the impact of dual diagnosis on cancer care and patient outcomes.

Panelists discuss how the landscape of small cell lung cancer (SCLC) treatment is rapidly evolving, highlighting key advances in immunotherapy, targeted treatments like tarlatamab, and ongoing research efforts, while emphasizing the importance of early diagnosis, appropriate staging, and personalized treatment approaches to improve patient outcomes and quality of life.

Panelists discuss how treatment options for small cell lung cancer (SCLC) extend beyond first-line therapies and the recently approved tarlatamab, exploring existing treatments in the second-line and beyond while also highlighting promising ongoing clinical trials and emerging therapies that show potential for improving outcomes in SCLC patients.

Panelists discuss how to determine the optimal timing for initiating immunotherapy in patients with small cell lung cancer (SCLC), considering the pros and cons of inpatient vs outpatient administration, while also addressing the unique barriers to diagnosing and treating SCLC compared with non–small cell lung cancer and exploring strategies to overcome these challenges.

Panelists discuss how to effectively collaborate with payers to ensure access to necessary medications for patients with small cell lung cancer (SCLC), while also exploring best practices for patient education and identifying valuable resources to share with those diagnosed with SCLC.

Panelists discuss how biomarker testing is currently utilized in the management of patients with small cell lung cancer (SCLC), including its timing within the treatment journey, while also exploring the existing unmet needs in biomarker testing for SCLC and potential strategies to address and overcome these challenges in the future.

Panelists discuss how the ADRIATIC trial investigating durvalumab in limited-stage small cell lung cancer (SCLC) has shown promising results, potentially addressing unmet needs in this patient population, and consider its potential impact on treatment algorithms and its possible emergence as a new standard of care if approved for this indication.

Panelists discuss how atezolizumab is being investigated in the NRG-LU005 trial for limited-stage small cell lung cancer (SCLC), comparing its trial design with that of the ADRIATIC study, while also exploring the potential benefits of using a single immunotherapy across all SCLC stages and considering treatment strategies for patients who progress from limited-stage to extensive-stage disease while on immunotherapy.

Panelists discuss how immunotherapies like durvalumab and atezolizumab have emerged as promising treatments for extensive-stage small cell lung cancer (SCLC), complementing traditional chemotherapy, and explore the results of key trials such as CASPIAN and IMpower133 while considering patient selection, treatment algorithms, and management of adverse events associated with these novel therapies.

Panelists discuss how tarlatamab, a bispecific T-cell engager therapy, received accelerated approval for extensive-stage small cell lung cancer (SCLC) in May 2024, examining its mechanism of action, pivotal clinical data, management of adverse events, practical considerations for administration, and its position within the SCLC treatment algorithm.

Panelists discuss how conventional therapies for extensive-stage and limited-stage small cell lung cancer (SCLC) have evolved, including the role of chemoradiotherapy (CRT) and its various schedules, while exploring unmet needs in extensive-stage settings and the potential for combining immunotherapies with CRT to improve treatment outcomes.

Panelists discuss how small cell lung cancer (SCLC) differs from non–small cell lung cancer in terms of staging, epidemiology, risk factors, prevention strategies, and prognosis, while also exploring the distinctions between limited-stage and extensive-stage SCLC and considering potential improvements in staging practices.

The panel provides insights on enhancing outcomes for patients with metastatic non-small cell lung cancer without targetable driver mutations.

September 27th 2024

October 27th 2026